As of 2025-07-01, the Intrinsic Value of Helix Biopharma Corp (HBP.TO) is -0.68 CAD. This HBP.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.95 CAD, the upside of Helix Biopharma Corp is -171.42%.
Based on its market price of 0.95 CAD and our intrinsic valuation, Helix Biopharma Corp (HBP.TO) is overvalued by 171.42%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.68 - -0.68 | -0.68 | -171.42% |
| P/E | (0.01) - (0.04) | (0.01) | -101.4% |
| DDM - Stable | (1.05) - (8.69) | (4.87) | -612.9% |
| DDM - Multi | (0.95) - (6.42) | (1.68) | -277.3% |
| Market Cap (mil) | 66.74 |
| Beta | 1.05 |
| Outstanding shares (mil) | 70.25 |
| Enterprise Value (mil) | 66.03 |
| Market risk premium | 5.10% |
| Cost of Equity | 9.21% |
| Cost of Debt | 5.00% |
| WACC | 6.45% |